Livtencity

Warnings and Precautions for Livtencity

Livtencity does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.

Reduced Antiviral Activity When Combined

Livtencity antagonizes the antiviral activity of ganciclovir and valganciclovir against CMV when used together. Coadministration with these medicines is not recommended.

Virologic Failure and Resistance

Reduced susceptibility to Livtencity can occur during treatment. Viral load should be monitored, and treatment reassessed if there is no improvement or if CMV DNA levels increase.

Drug Interactions

Livtencity has significant drug interactions, including increased concentrations of immunosuppressants such as tacrolimus, cyclosporine, and sirolimus, which require frequent monitoring during treatment.

Taste Disturbance

Dysgeusia (altered taste) is a commonly reported side effect and may affect appetite and nutritional intake in some patients.

How to Access Livtencity in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation and Availability of Livtencity

Livtencity is manufactured and marketed by Takeda Pharmaceuticals America, Inc. It is sourced through authorized distribution channels for patients seeking named-patient import into India.

Required Documentation

Patients typically need a valid prescription from a treating transplant physician or infectious disease specialist confirming refractory CMV infection and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.

Availability

As an FDA-approved therapy for refractory post-transplant CMV infection, Livtencity is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.

Sourcing and Delivery of Livtencity

NPP sources Livtencity directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.

Storage and Handling

Livtencity should be stored at 20°C to 25°C, with brief excursions to 15°C to 30°C permitted, and this condition is maintained throughout transit.

Delivery Timelines

Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.

Availability of Livtencity Across Major Cities in India

Patients across India can access Livtencity through NPP's regulated import pathway, with transplant and infectious disease specialists in major cities supporting the treatment process.

Mumbai

Leading hospitals in Mumbai support transplant infectious disease care coordination and documentation for Livtencity access.

Delhi

Delhi's major hospitals assist patients with prescription support and documentation for Livtencity.

Bangalore

Bangalore's specialist network offers access coordination for eligible transplant patients seeking Livtencity.

Chennai

Chennai-based transplant specialists coordinate Livtencity access alongside comprehensive post-transplant care.

Hyderabad

Hyderabad's care institutions support patients pursuing Livtencity therapy.

Kolkata

Kolkata's specialist centers help coordinate documentation and treatment access for Livtencity.

Pune

Pune-based specialists assist with prescription support and Livtencity treatment planning.

Ahmedabad

Ahmedabad's specialty hospitals support the import and treatment process for Livtencity.

Kochi

Kochi's specialist units assist patients with the documentation needed for Livtencity access.

Chandigarh

Chandigarh's care centers support Livtencity treatment coordination for patients from North India.

Jaipur

Jaipur's specialists help patients navigate the Livtencity access process.

Lucknow

Lucknow-based centers assist patients pursuing Livtencity therapy.

Bhubaneswar

Bhubaneswar's institutions support access to Livtencity for eligible patients.

Guwahati

Guwahati's specialists help coordinate Livtencity access for patients across the Northeast.

Patients in other cities across India can also access Livtencity through NPP's nationwide coordination network.